EA201692039A1 - ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ - Google Patents

ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ

Info

Publication number
EA201692039A1
EA201692039A1 EA201692039A EA201692039A EA201692039A1 EA 201692039 A1 EA201692039 A1 EA 201692039A1 EA 201692039 A EA201692039 A EA 201692039A EA 201692039 A EA201692039 A EA 201692039A EA 201692039 A1 EA201692039 A1 EA 201692039A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human vγ9vδ2
immunoglobulins
cell receptors
binding human
vγ9vδ2
Prior art date
Application number
EA201692039A
Other languages
English (en)
Other versions
EA039086B1 (ru
Inventor
Йоханнес Йелле Ван Дер Влит
Рене Корнелия Герарда Де Брейн
Таня Дениз Де Грюейль
Хендрик Маринус Виллем Верхель
Original Assignee
Стихтинг Вюмк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стихтинг Вюмк filed Critical Стихтинг Вюмк
Publication of EA201692039A1 publication Critical patent/EA201692039A1/ru
Publication of EA039086B1 publication Critical patent/EA039086B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретение относится к области медицины и к области иммунологии и, в частности, относится к молекулам иммуноглобулинов, связывающим человеческий Vγ9Vδ2 Т-клеточный рецептор. Молекулы иммуноглобулинов, связывающие человеческий Vγ9Vδ2 Т-клеточный рецептор, в частности, предназначены для применения при лечении и/или являются полезными в анализах с использованием человеческих Vγ9Vδ2 Т-клеток, где человеческие Vγ9Vδ2 Т-клетки могут быть модулированы.
EA201692039A 2014-04-10 2015-04-10 Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы EA039086B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2012604 2014-04-10
PCT/NL2015/050235 WO2015156673A1 (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Publications (2)

Publication Number Publication Date
EA201692039A1 true EA201692039A1 (ru) 2017-05-31
EA039086B1 EA039086B1 (ru) 2021-12-01

Family

ID=50896416

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201692039A EA039086B1 (ru) 2014-04-10 2015-04-10 Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
EA202192165A EA202192165A1 (ru) 2014-04-10 2015-04-10 Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202192165A EA202192165A1 (ru) 2014-04-10 2015-04-10 Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы

Country Status (11)

Country Link
US (4) US10501540B2 (ru)
EP (1) EP3129404A1 (ru)
JP (4) JP6617138B2 (ru)
KR (2) KR102601469B1 (ru)
CN (2) CN106536557B (ru)
AU (3) AU2015244489B2 (ru)
CA (1) CA2948812A1 (ru)
EA (2) EA039086B1 (ru)
MX (2) MX2016013332A (ru)
SG (2) SG11201609417VA (ru)
WO (1) WO2015156673A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10356636B2 (en) * 2017-04-03 2019-07-16 Qualcomm Incorporated Techniques and apparatuses to improve drone-mounted user equipment performance
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
EP3818079A4 (en) * 2018-07-05 2022-04-06 Novobind Livestock Therapeutics Inc. ANTIBODIES AGAINST POULTRY PATHOGENS AND THEIR USE
EP3853256A1 (en) 2018-09-19 2021-07-28 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP2022516964A (ja) 2019-01-07 2022-03-03 シャタック ラボ，インコーポレイテッド ガンマデルタｔ細胞を調節するためのヘテロ二量体タンパク質
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
US20220135694A1 (en) 2019-02-01 2022-05-05 Lava Therapeutics B.V. Novel cd40-binding antibodies
JP7308477B2 (ja) * 2019-03-11 2023-07-14 パナソニックＩｐマネジメント株式会社 抗体、複合体、それを用いた検出装置及び検出方法
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATING T-LYMPHOCYTE-MEDIATED IMMUNITY
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
AR123935A1 (es) * 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
EP4240405A1 (en) 2020-11-05 2023-09-13 Mendus B.V. Use of tumor-independent antigens in immunotherapies
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
KR20230157933A (ko) 2020-12-10 2023-11-17 라바 테라퓨틱스 엔.브이. 감마-델타 t 세포 수용체에 결합하는 항체
US20240141071A1 (en) 2021-02-26 2024-05-02 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
TW202328193A (zh) 2021-09-13 2023-07-16 美商健生生物科技公司 用於治療癌症的CD33 x Vδ2多特異性抗體
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
TW202334233A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 結合γδ T細胞之多肽及其用途
CN115043935B (zh) * 2022-03-31 2023-06-27 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN116178538A (zh) * 2023-01-05 2023-05-30 暨南大学 靶向热休克蛋白70的纳米抗体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
EP1627231A2 (en) * 2003-05-23 2006-02-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improvements to gamma delta t cell-mediated therapy
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CN102154205A (zh) * 2011-01-31 2011-08-17 郑骏年 高纯度、高细胞毒活性的γδT细胞的制备方法
WO2013110531A1 (en) * 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (zh) * 2012-02-10 2015-05-13 深圳市合一康生物科技股份有限公司 一种人γδT细胞的形态学、纯度及免疫表型检测方法
EP3333186B9 (en) * 2012-03-28 2023-10-04 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange

Also Published As

Publication number Publication date
AU2015244489B2 (en) 2020-08-27
AU2015244489A1 (en) 2016-12-01
JP2020029461A (ja) 2020-02-27
CN106536557B (zh) 2021-05-04
EA202192165A1 (ru) 2021-12-31
AU2020213325B2 (en) 2023-03-30
KR102601469B1 (ko) 2023-11-14
US20190263908A1 (en) 2019-08-29
KR102359264B1 (ko) 2022-02-04
MX2021009674A (es) 2021-09-08
JP6617138B2 (ja) 2019-12-11
CN113105550A (zh) 2021-07-13
EA039086B1 (ru) 2021-12-01
US20220098301A1 (en) 2022-03-31
CN106536557A (zh) 2017-03-22
JP2017513521A (ja) 2017-06-01
JP7342202B2 (ja) 2023-09-11
EP3129404A1 (en) 2017-02-15
AU2020213325A1 (en) 2020-08-27
US20230212290A1 (en) 2023-07-06
WO2015156673A1 (en) 2015-10-15
US11384145B2 (en) 2022-07-12
MX2016013332A (es) 2017-05-01
KR20170019343A (ko) 2017-02-21
AU2023204215A1 (en) 2023-07-20
JP2022136078A (ja) 2022-09-15
US20170029506A1 (en) 2017-02-02
US10501540B2 (en) 2019-12-10
SG11201609417VA (en) 2016-12-29
JP7094931B2 (ja) 2022-07-04
CA2948812A1 (en) 2015-10-15
JP2023165723A (ja) 2023-11-17
SG10202007233TA (en) 2020-09-29
KR20220021015A (ko) 2022-02-21

Similar Documents

Publication Publication Date Title
EA201692039A1 (ru) ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201892193A1 (ru) Химерные рецепторы к flt3 и способы их применения
PH12018501882A1 (en) Binding proteins and methods of use thereof
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201790288A1 (ru) Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
BR112016030740A2 (pt) diacorpos heterodiméricos biespecíficos e seus usos
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201891299A1 (ru) Терапевтические антитела к cd9
EA201400447A1 (ru) АНТИТЕЛА К CD1d
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d

Legal Events

Date Code Title Description
HC1A Change in name of an applicant in a eurasian application